Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569389 | 0.84 | BACE1 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5569783 | 0.81 | KAT8 (0.57) | ESR1ESR2KAT8ALOX15PPARA | |
| SCHEMBL22907008 | 0.80 | CYP4A11 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL529618 | 0.79 | ESR1 (0.68) | ESR1ESR2ALOX15HPGDNPSR1 | |
| SCHEMBL7854193 | 0.79 | GAA (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28773091 | 0.79 | PPARA (0.58) | KAT8ALDH1A1ALOX15KDM4EGAA | |
| SCHEMBL24106426 | 0.78 | ESR1 (0.40) | ESR1ALDH1A1ALOX15KDM4EGAA | |
| SCHEMBL20725428 | 0.78 | KAT8 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3027090 | 0.78 | CYP4A11 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15498456 | 0.78 | PPARA (0.50) | KAT8ALDH1A1ALOX15KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210388007-A1 | COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | WUHAN UNIVERSITY (CN) | 2021-12-16 | — | — | US | disclosed |
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| EP-1537065-B1 | ANALOGUES OF VITAMIN D | GALDERMA RES & DEV (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
| EP-1537065-A1 | ANALOGUES OF VITAMIN D | Galderma Research & Development, S.N.C. (FR) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020379-A1 | ANALOGUES OF VITAMIN D | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | ESR1 1406/4885ESR2 851/4885CA12 4456/4885 |
| US-20210388007-A1 | COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | CYP2F1, CYP4F3, CFH | ESR1 2882/4885ESR2 1691/4885CA12 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.